A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6897-6904

  Mayer, Erica L ^a   Baurain, Jean Francois ^b   Sparano, Joseph ^d   Strauss, Lewis ^e   Campone, Mario ^f   Fumoleau, Pierre ^g   Rugo, Hope ^h   Awada, Ahmad ^c   Sy, Oumar ^e   Llombart Cussac, Antonio ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d ALBERT EINSTEIN CANCER CENTER   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CONTROL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SRC-FAMILY KINASES; THIAZOLES;

EID: 80455132309     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0070     Document Type: Article

References (32)

1. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, et al. Dasatinib as a single-agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011;17:XXX-XXX
2. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609. (Pubitemid 28034534)
3. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA, et al. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986;261:13754-9. (Pubitemid 17196400)
4. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383-8. (Pubitemid 27014075)
5. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33. (Pubitemid 37022641)
6. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005;105:1508-14. (Pubitemid 40223667)
7. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
8. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009;175:1389-97.
9. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010;70:2296-306.
10. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. BiochemBiophys ResCommun 2006;341:73-81. (Pubitemid 43118368)
11. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004;23:7979-89. (Pubitemid 39480682)
12. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-86.
13. Ishizawar R, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007;26:3503-10. (Pubitemid 46816756)
14. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994;14:735-43.
15. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318:161-72.
16. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010;19:415-25.
17. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41. (Pubitemid 43882349)
18. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib (BMS-354825), a Src and multi-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40.
19. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
20. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010;6:195-7.
21. Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol 2008;48:1254-69.
22. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative"breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26. (Pubitemid 47596452)
23. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38. (Pubitemid 46424242)
24. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
25. Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, et al. An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 2009;11:R55.
26. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006;5:3023-31. (Pubitemid 46092043)
27. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74. (Pubitemid 43945756)
28. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007;117:2205-15. (Pubitemid 47219565)
29. Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol 2007;60:535-43. (Pubitemid 47084264)
30. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115:57-67.
31. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42.
32. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 2009;283:143-51.